A large AI-driven study of 3,476 cancer patients, presented at ESMO 2025, reveals that thymic health is strongly linked to ...
Researchers have developed self-assembling peptide nanotubes that deliver doxorubicin directly into the nucleus of ...
A new PNAS study unveils a hidden vulnerability of prostate cancer: the protein-disulfide isomerases , which stabilize (AR) ...
Researchers have developed a groundbreaking LED-based cancer therapy using tin oxide (SnOx) nanoflakes that selectively ...
Researchers at the Institut Pasteur and Inserm have developed a novel triple-therapy that reprograms how B cell cancers ...
The FDA has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as the first and only immunotherapy for the adjuvant ...
Bristol Myers Squibb (BMS) has announced the acquisition of Orbital Therapeutics, a privately held biotech specializing in ...
The Phase III TROPION-Breast02 trial demonstrated that datopotamab deruxtecan (Datroway) achieved a statistically significant and clinically meaningful improvement in both overall and progression-free ...
The FDA has approved atezolizumab (Tecentriq) plus lurbinectedin (Zepzelca) as the first combination maintenance therapy for ...
ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...
The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果